VITAL-Z

Indications

• Fluid and electrolyte imbalances
• Hypoglycemia
• Nutritional supplementation
• Diabetic emergencies

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing guidelines.

Adults: The dosage varies based on the clinical condition and specific formulation used. For intravenous administration, consult product literature for precise dosing.

Mechanism of action

Glucose supplies energy to tissues by undergoing glycolysis, which begins with its phosphorylation by hexokinase to form glucose 6-phosphate. This activates glucose for breakdown, ultimately generating ATP and NADH. The aerobic metabolism of glucose can yield up to 36 ATP molecules. Glucose also serves as a precursor for other biomolecules and regulates various physiological processes including gene transcription and hormone secretion.

Pharmacodynamics

Glucose is an obligatory energy source for cellular activities and plays a significant role in metabolic signaling. It is oxidized to yield energy through glycolysis, the citric acid cycle, and oxidative phosphorylation. Glucose can be converted into fat for energy storage and is stored as glycogen in the liver and muscles. Its administration increases blood glucose levels and stimulates insulin secretion, particularly through oral routes that activate gut incretin hormones.

Pharmacokinetics

Glucose is rapidly absorbed from the gastrointestinal tract or directly into the bloodstream when administered intravenously. It is distributed widely throughout the body and metabolized primarily in tissues requiring energy. The body maintains glucose homeostasis through regulatory mechanisms involving insulin and glucagon. Excess glucose can be stored as glycogen or converted to triglycerides for long-term energy storage.

Adverse effects

• Hyperglycemia
• Increased osmolarity
• Fluid overload
• Electrolyte imbalances

Interactions

• Insulin - may require dose adjustments

Precautions

• Use with caution in patients with diabetes mellitus
• Monitor blood glucose levels in patients receiving parenteral glucose
• Adjust dosage in renal impairment

Pregnancy

Glucose is generally considered safe in pregnancy; however, monitoring is advised, especially in diabetic patients.

Breast-feeding

Glucose is considered safe during breastfeeding, as it is a natural sugar found in breast milk.

Storage

Store at room temperature, away from light. Avoid freezing.

Formulations

• Glucose 5% solution for infusion
• Glucose 10% solution for infusion
• Glucose 0.9% solution for injection
• Glucose sodium chloride combination solutions

Indications

• Vitamin C deficiency
• Scurvy
• As an adjunct in the treatment of iron deficiency anemia
• Support for immune function
• Antioxidant therapy

Dosage

Adults: Refer to the BNF for specific

Mechanism of action

Ascorbic acid functions primarily as a reducing agent, donating electrons to various biochemical reactions. It is involved in the hydroxylation of proline and lysine residues in collagen synthesis, which is essential for maintaining connective tissue integrity. As an antioxidant, it also helps to regenerate other antioxidants, such as vitamin E, thereby protecting cells from oxidative damage. Furthermore, it enhances the absorption of non-heme iron from the gastrointestinal tract, promoting better iron utilization in the body.

Pharmacodynamics

Ascorbic acid is crucial for metabolic processes, including the synthesis of collagen and certain neurotransmitters. Its antioxidant properties help mitigate oxidative stress, which can lead to cellular damage and various diseases. The vitamin's role in iron absorption is particularly significant in preventing iron-deficiency anemia. The therapeutic effects of ascorbic acid are dose-dependent, with higher doses often resulting in more pronounced antioxidant effects.

Pharmacokinetics

Ascorbic acid is readily absorbed in the small intestine, with peak plasma concentrations occurring within 2 to 4 hours after oral administration. The bioavailability of ascorbic acid decreases at higher doses due to saturation of the transport mechanisms. It is distributed throughout bodily fluids and tissues, with highest concentrations found in the adrenal glands, pituitary gland, and leukocytes. The elimination half-life varies, typically ranging from 8 to 40 days, depending on the dose and the individual's renal function. Ascorbic acid is excreted primarily through the kidneys, with renal clearance being influenced by plasma concentration and renal health.

Interactions

• ascorbic acid + iron chelators: Unknown (increases risk of cardiovascular adverse effects)
• ascorbic acid + deferiprone: Unknown (increases risk of cardiovascular adverse effects)
• ascorbic acid + desferrioxamine: Unknown (increases risk of cardiovascular adverse effects)

Pregnancy

Ascorbic acid is generally considered safe during pregnancy but should be used with caution and only when necessary.

Breast-feeding

Ascorbic acid is excreted in breast milk and is generally considered safe during breastfeeding.

Storage

Store at room temperature, away from light and moisture.

Indications

• Malabsorption syndromes
• Crohn's disease
• Cystic fibrosis
• Short bowel syndrome
• Severe food allergies
• Inability to meet nutritional needs through standard diets

Dosage

Children: Refer to specific formulations for dosing, as paediatric dosages depend on the product and the child's nutritional needs.

Adults: Refer to specific formulations for dosing, as adult dosages vary based on the product used and the patient's nutritional requirements.

Mechanism of action

Elemental formulations provide nutrients in their simplest forms, which are readily absorbed in the small intestine. This bypasses complex digestive processes, making them suitable for individuals with compromised digestion or absorption capabilities. The nutrients in these formulations include amino acids, simple carbohydrates, and fatty acids, which can be directly utilized by the body's metabolic pathways.

Pharmacodynamics

Elemental formulations help restore nutritional balance by supplying essential macronutrients and micronutrients needed for metabolic processes. They support growth, maintain energy levels, and promote healing in patients with malabsorption or increased nutritional needs. The bioavailability of nutrients in elemental forms is typically high, allowing for efficient uptake and utilization by the body.

Pharmacokinetics

Following administration, elemental nutrients are absorbed in the gastrointestinal tract, primarily in the jejunum and ileum. The rate of absorption can vary based on the specific formulation and the individual's gastrointestinal health. Once absorbed, these nutrients enter systemic circulation and are transported to various tissues for utilization in metabolic processes. The elimination of unabsorbed nutrients occurs primarily through feces.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Stomach cramps
• Dark stools
• Metallic taste
• Allergic reactions

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for signs of iron overload in patients receiving multiple iron products.
• Assess for the need for supplementation in patients with conditions causing malabsorption.

Pregnancy

Iron is essential during pregnancy, but supplementation should be guided by clinical need and under healthcare supervision.

Breast-feeding

Iron is excreted in breast milk; supplementation may be necessary depending on maternal iron status.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Oral tablets
• Liquid formulations
• Injectable solutions

Dosage

Children: Refer to BNF for Children for specific dosing guidance, as heptachlor usage is largely restricted.

Adults: Refer to BNF for specific dosing information, as heptachlor is not commonly used in clinical settings due to safety concerns.

Mechanism of action

Heptachlor mimics the action of picrotoxin, inhibiting gamma-aminobutyric acid (GABA)-stimulated chloride uptake, which leads to nerve excitation in insects. It competes for binding sites in the brain, causing central nervous system stimulation and resulting in increased transmitter release. This mechanism can lead to increased excitability and potentially toxic effects in target organisms.

Pharmacodynamics

As a neurotoxic agent, heptachlor causes hyperactivity and central nervous system stimulation in insects. Its effects on GABA receptors disrupt normal inhibitory neurotransmission, resulting in uncontrolled neuronal firing. While primarily studied in insects, similar mechanisms may be inferred in higher organisms, including potential neurotoxic effects in humans.

Pharmacokinetics

Heptachlor is lipophilic, leading to significant bioaccumulation in organisms and environmental persistence. It is metabolized in the liver to heptachlor epoxide, which is the more toxic form. The elimination half-life varies but can be prolonged due to its fat solubility and tendency to accumulate in fatty tissues.

Pregnancy

Heptachlor is classified as a category B drug. Animal studies have not shown any harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed.

Breast-feeding

It is not known if heptachlor is excreted in human milk. Caution should be exercised when administering heptachlor to a nursing mother.

Storage

Store in a cool, dry place, away from direct sunlight. Keep container tightly closed and out of reach of children.

Dosage

Children: Refer to specific formulation guidelines for pediatric dosing, as heptahydrate is generally used in conjunction with other active ingredients.

Adults: Refer to specific formulation guidelines for dosing, as heptahydrate is typically a component rather than an active agent.

Mechanism of action

Heptahydrate itself does not have a specific pharmacological action as it is generally a structural component in formulations. However, the active ingredients in heptahydrate formulations may exert their effects through various mechanisms depending on their specific pharmacology.

Pharmacodynamics

Pharmacodynamics of heptahydrate salts is largely influenced by the active pharmaceutical ingredients they are combined with. The presence of water molecules can enhance solubility, thereby improving the absorption and overall efficacy of the drug when administered. The hydration state can also play a role in the release profile of the drug from solid dosage forms.

Pharmacokinetics

The pharmacokinetics of heptahydrate formulations depend on the specific active ingredient they harbor. The dissolution rate can be affected by the hydration state, leading to variations in absorption rates. Generally, the pharmacokinetic profile would include absorption, distribution, metabolism, and excretion characteristics of the active pharmaceutical ingredients rather than the heptahydrate component itself.

Indications

• Sweetening agent in food and beverages
• Ingredient in pharmaceutical formulations
• Source of quick energy

Dosage

Children: Refer to specific formulations and clinical guidelines for dosing, as sucrose does not have a standardized dosage. Typically used as needed for sweetening.

Adults: Refer to specific formulations and clinical guidelines for dosing, as sucrose does not have a standardized dosage. Typically used as needed for sweetening.

Mechanism of action

Sucrose is metabolized in the body to glucose and fructose, which are then used as energy sources. It does not have a specific pharmacological mechanism of action but contributes to energy metabolism via the glycolytic and citric acid pathways.

Pharmacodynamics

Upon ingestion, sucrose is hydrolyzed by the enzyme sucrase into its constituent monosaccharides, glucose and fructose. These monosaccharides are absorbed in the small intestine and enter the bloodstream, leading to a rise in blood glucose levels. This process provides a quick source of energy for cellular functions.

Pharmacokinetics

Sucrose is rapidly absorbed in the gastrointestinal tract after hydrolysis. Its absorption depends on the presence of sucrase in the intestine. Once in the bloodstream, glucose can be utilized by cells or stored as glycogen in the liver and muscles. The elimination half-life of sucrose itself is not well-defined as it is quickly broken down and utilized.

Pregnancy

Sucrose is generally regarded as safe during pregnancy when consumed in moderation as part of a balanced diet.

Breast-feeding

Sucrose is considered safe during breastfeeding when consumed in normal dietary amounts.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Granules
• Tablets

Mechanism of action

Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity. Vascular calcification is a hallmark of type 2 diabetes. Glucose stimulates calcification in culture of vascular smooth muscle cells (VSMCs) but the underlying mechanisms remain obscure. We observed that high glucose levels stimulated mouse and human VSMC trans-differentiation into chondrocytes, with increased levels of Sox9, type II collagen, glycosaminoglycan and Runx2 expression, and increased alkaline phosphatase activity and mineralization. These effects were associated with increased expression of IL-1beta, which stimulated alkaline phosphatase and calcification, suggesting that glucose induces chondrocyte differentiation of VSMCs, possibly through IL-1beta activation.

Pharmacodynamics

Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.

Mechanism of action

EVIDENCE INDICATES THAT CYCLODIENE-TYPE-INSECTICIDES, EG, HEPTACHLOR EPOXIDE, MIMIC ACTION OF PICROTOXININ. THESE INSECTICIDES INHIBIT THE GAMMA-AMINOBUTYRIC ACID-STIMULATED CHLORIDE UPTAKE IN COXAL MUSCLE OF AMERICAN COCKROACH, & DIRECTLY COMPETE AGAINST LABELED DIHYDROPICROTOXININ FOR BINDING IN THE RAT BRAIN SYNAPTOSOMES. MOREOVER, SEVERAL CYCLODIENE RESISTANT INSECT STRAINS ARE RESISTANT TO PICROTOXININ. THIS CROSS-RESISTANCE IS SPECIFIC TO PICROTOXININ & DOES NOT EXTEND TO OTHER NEUROEXCITANTS. THESE INSECTICIDES, LIKE PICROTOXININ, CAUSE CENTRAL NERVOUS EXCITATION BY STIMULATING TRANSMITTER RELEASE. THESE RESULTS INDICATE THAT SOME OF THE NERVE EXCITATION SYMPTOMS THAT INSECTICIDES CAUSE ARE LIKELY DUE TO THEIR INTERACTION WITH PICROTOXININ RECEPTOR. HEPTACHLOR WAS EVALUATED FOR GENOTOXICITY & EPIGENETIC MEMBRANE EFFECTS. IT WAS NON-GENOTOXIC IN ARLHGPRT MUTAGENESIS ASSAY IN WHICH THE GENOTOXIC CARCINOGENS 7,12-DIMETHYLBENZ(A)ANTHRACENE & BENZO(A)PYRENE INDUCED SIGNIFICANT INCR IN MUTANT INCIDENCE. HEPTACHLOR INHIBITED INTERCELLULAR COMMUNICATION BETWEEN CULTURED LIVER CELLS, A PROPERTY DEMONSTRATED BY MANY TUMOR PROMOTING AGENTS, WHEREAS, BENZO(A)PYRENE DID NOT PRODUCE THIS EPIGENETIC EFFECT. The actions of the polychlorocycloalkane insecticide heptachlor, and its epoxide metabolite, were examined on GABA receptors in insects and vertebrates. Electrophysiological experiments on the cell body of the cockroach (Periplaneta americana) fast coxal depressor motor neuron (Df), and GABA-activated (36) Cl- uptake experiments on microsacs perpared from cockroach ventral nerve cords showed that both heptachlor and heptachlor epoxide blocked functional GABA receptors. The block appeared to be non-competitive and was voltage-independent over the membrane potential range -75 mV to -110 mV. There was no significant difference between the potencies of heptachlor and heptachlor epoxide in the functional assays for insect GABA receptors. Both compounds inhibited (35)S-t-butylbicyclophosphorothionate binding in insects and vertebrates. The findings provide further evidence for block of an insect GABA receptor/Cl- channel by the cyclodiene class of polychlorocycloalkanes, and reveal differences in the insecticide (35)S-t-butylbicyclophosphorothionate binding site interactions of insects and vertebrates. The effects of heptachlor on oxidative phosphorylation and electron transport in male Donryu rat liver mitochondria were investigated. The effects of 50 uM heptachlor on the respiratory activity of isolated liver mitochondria was tested in the presence of added succinate as a substrate. The effects of 100 uM heptachlor was tested in the presence of three kinds of substrates: succinate, beta-hydroxybutylate, and ascorbate plus N,N,N'N'-tetramethylphenylene-diamine. Heptachlor at 50 uM greatly inhibited the state 3 respiration, but inhibited the state 4 respiration hardly at all. The inhibition was released by 2,4-dinitrophenol. The higher dose suppressed state 3 and state 4 respiration almost completely with succinate as substrate. The findings suggest that the function of the electron transport system was also suppressed by the higher heptachlor dose even without oxidative phosphorylation.